Investigational antiviral drugs for the treatment of COVID-19

被引：0
|
作者：
Vegivinti, C. T. R. [1 ]
Assi, M. [2 ]
Talwani, R. [3 ]
Koblizek, V [4 ,5 ]
Burke, K. [6 ]
Temesgen, Z. [7 ]
机构：
[1] Manipal Acad Higher Educ MAHE, Kasturba Med Coll, Dept Gen Med, Manipal, Karnataka, India
[2] Virginia Commonwealth Univ, Dept Internal Med, Richmond, VA USA
[3] Univ Maryland, Div Infect Dis, Baltimore, MD 21201 USA
[4] Charles Univ Prague, Univ Hosp Hradec Kralove, Prague, Czech Republic
[5] Charles Univ Prague, Fac Med, Prague, Czech Republic
[6] Wolters Kluwer, Clin Effectiveness, Indianapolis, IN USA
[7] Mayo Clin & Mayo Fdn, Div Infect Dis, Rochester, MN USA
来源：
DRUGS OF THE FUTURE | 2021年 / 46卷 / 09期
基金：
美国国家卫生研究院;
关键词：
COVID-19; SARS-CoV-2; Remdesivir; Hydroxychloroquine; Lopinavir/ritonavir; Ribavirin; Ivermectin; Favipiravir; Umifenovir; Camostat; Nafamostat Nitazoxanide; DAS-181; RESPIRATORY SYNDROME CORONAVIRUS; SIALIDASE FUSION PROTEIN; NAFAMOSTAT MESILATE; INTERFERON-THERAPY; RIBAVIRIN; INHIBITOR; DAS181; IVERMECTIN; RITONAVIR; INFECTION;
D O I：
10.1358/dof.2021.46.9.3293585
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
A large number of candidate drugs are undergoing evaluation for their potential to limit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication. Clinical trial data are slowly emerging for several of these agents. We provide a review of candidate antiviral agents registered in ClinicalTrials.gov , which have clinical efficacy data, provide the rationale for their consideration for this purpose, and summarize available data on their efficacy and safety.
引用
收藏
页码：697 / 710
页数：14
相关论文
共 50 条
  • [1] Investigational antiviral drugs for the treatment of COVID-19 patients
    Beheshtirouy, Samineh
    Khani, Elnaz
    Khiali, Sajad
    Entezari-Maleki, Taher
    ARCHIVES OF VIROLOGY, 2022, 167 (03) : 751 - 805
  • [2] Investigational antiviral drugs for the treatment of COVID-19 patients
    Samineh Beheshtirouy
    Elnaz Khani
    Sajad Khiali
    Taher Entezari-Maleki
    Archives of Virology, 2022, 167 : 751 - 805
  • [3] EFFECTS OF ANTIVIRAL DRUGS ON COVID-19 TREATMENT
    Luo, Min
    Jia, Junbo
    Wang, Ruiqi
    Wang, Lin
    DISCRETE AND CONTINUOUS DYNAMICAL SYSTEMS-SERIES B, 2024, 29 (05): : 2353 - 2367
  • [4] Efficacy of the current investigational drugs for the treatment of COVID-19: a scoping review
    Wadaa-Allah, Ahmed
    Emhamed, Marwa S.
    Sadeq, Mohammed A.
    Ben Hadj Dahman, Nesrine
    Ullah, Irfan
    Farrag, Nesrine S.
    Negida, Ahmed
    ANNALS OF MEDICINE, 2021, 53 (01) : 318 - 334
  • [5] Antiviral treatment of COVID-19
    Simsek Yavuz, Serap
    Unal, Serhat
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2020, 50 : 611 - 619
  • [6] Safety and Efficacy of Antiviral Drugs for the Treatment of COVID-19: A Systematic Review
    Nie, Zhenwang
    Sun, Tao
    Zhao, Fangcheng
    INFECTION AND DRUG RESISTANCE, 2022, 15 : 4457 - 4466
  • [7] Association of Antiviral Drugs for the Treatment of COVID-19 With Acute Renal Failure
    Kamo, Masahiro
    Sogawa, Rintaro
    Shimanoe, Chisato
    IN VIVO, 2024, 38 (04): : 1841 - 1846
  • [8] The black market for covid-19 antiviral drugs
    Plata, G. Gabriel
    BMJ-BRITISH MEDICAL JOURNAL, 2022, 376
  • [9] Antiviral Drugs for COVID-19 in Vaccinated Outpatients
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2023, 65 (1671): : 33 - 34
  • [10] Efficiency of antiviral treatment in COVID-19
    Negrut, Nicoleta
    Codrean, Adriana
    Hodisan, Ioana
    Bungau, Simona
    Tit, Delia Mirela
    Marin, Ruxandra
    Behl, Tapan
    Banica, Florin
    Diaconu, Camelia C.
    Nistor-Cseppento, Delia Carmen
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 21 (06)
12345